Oral palonosetron noninferior to IV formulation for CINV prevention
the ONA take:
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV), according to a study published in the October 2015 issue of the journal Supportive Care in Cancer.
For the study, a team of researchers led by Prof. Dr. med. Meinolf Karthaus of the Department of Hematology and Oncology at Klinikum Neuperlach in Munich, Germany, sought to compare the efficacy and safety of oral palonosetron with intravenous palonosetron for the prevention cisplatin-based highly emetogenic chemotherapy.
Researchers enrolled 743 chemotherapy-naive adults with malignant solid tumors initiating cisplatin-based chemotherapy. Patients were randomly assigned to receive palonosetron 0.50mg orally or 0.25mg intravenously plus oral dexamethasone.
Results showed that the complete response rate in the acute phase was higher than 86% in both treatment arms and the safety profiles were comparable.
Treatment-emergent adverse events related to palonosetron occurred in 3.2% of patients in the oral palonosetron group and 6.5% in the intravenous group.
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|